within Pharmacolibrary.Drugs.ATC.C;

model C02CA02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.33,
    Cl             = 3.116666666666667e-05,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0111,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.004666666666666667,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C02CA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Indoramin is a selective α1-adrenergic receptor antagonist used primarily as an antihypertensive agent and for the symptomatic management of benign prostatic hyperplasia. It is not widely used or available in many countries today, as more modern alternatives have replaced it in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters as reported in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Schabort, I, et al., &amp; Pierce, DM (1990). The pharmacokinetics of oral indoramin during pregnancy. <i>British journal of clinical pharmacology</i> 29(4) 397–401. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.1990.tb03656.x\">10.1111/j.1365-2125.1990.tb03656.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2328193/\">https://pubmed.ncbi.nlm.nih.gov/2328193</a></p></li><li><p>Norbury, HM, et al., &amp; Warrington, SJ (1984). Pharmacokinetics of oral indoramin in elderly and middle-aged female volunteers. <i>European journal of clinical pharmacology</i> 27(2) 247–249. DOI:<a href=\"https://doi.org/10.1007/BF00544054\">10.1007/BF00544054</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6499905/\">https://pubmed.ncbi.nlm.nih.gov/6499905</a></p></li><li><p>Draffan, GH, et al., &amp; Dollery, CT (1976). Pharmacokinetics of indoramin in man. <i>British journal of clinical pharmacology</i> 3(3) 489–495. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.1976.tb00626.x\">10.1111/j.1365-2125.1976.tb00626.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/788751/\">https://pubmed.ncbi.nlm.nih.gov/788751</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C02CA02;
